The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of multiple myeloma. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of multiple myeloma therapy, several agents entered the market in 2019 and 2020 (namely, Blenrep, Xpovio, and Sarclisa), and the late-phase pipeline remains buoyant. Indeed, immense clinical and commercial potential remains for therapies with improved efficacy and novel mechanisms of action that can fulfill the needs of underserved patient segments, such as smoldering multiple myeloma.
- What is the size of the drug-treatable multiple myeloma population, and will drug-treatment rates vary over time?
- How will the use of Revlimid and Velcade change over the forecast period? What impact will their expected generic erosion have on the multiple myeloma market?
- What are thought leaders’ opinions of novel agents such as CAR T-cell therapies and the SC formulation of Darzalex?
- What are the key drivers of and constraints in the multiple myeloma therapy market? How will the entry of new agents shape the market?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and country-specific surveys with 210 hematologist-oncologists treating multiple myeloma.
Epidemiology: Incidence of multiple myeloma by country, segmented by symptom.
Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and II products.